<DOC>
	<DOC>NCT00777998</DOC>
	<brief_summary>The present study will be a multicenter, prospective phase II-study investigating safety and efficacy of the combination of auto-allo tandem stem cell transplantation in patients with multiple myeloma and age of &gt;_60 years, followed by maintenance therapy with low-dose Thalidomide and Donor Lymphocyte Infusions.</brief_summary>
	<brief_title>Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Multiple Myeloma Stage II or III acc. to Salmon and Durie Patient's age 1860 years Patient's written informed consent Women and men capable of reproduction must agree to use adequate contraceptive measures (condom, IUD, oral contraceptives) until three months after termination of treatment a maximum of eight chemotherapy cycles prior to registration (CR/ PR/ MR/ or PD) More than eight chemotherapy cycles prior to registration severe irreversible renal, hepatic, pulmonary or cardiac disease, such as total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level Left ventricular ejection fraction &lt; 30 % Creatinine Clearance &lt; 30 ml/min DLCO &lt; 35 % and/or receiving supplementary continuous oxygen Positive serology for HIV Pregnant or lactating women Participation in another trial at the time of registration Preceding autologous stem cell transplantation age &gt; 61 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>DLI</keyword>
</DOC>